Uveal melanoma: Natural history and treatment options for metastatic disease

Melanoma Research

Volumn 9, Issue 6, 1999, Pages 575-581

  Woll E ^b   Bedikian, A ^a   Legha, S S ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Eye tumour; Metastatic disease; Uveal melanoma

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; DACARBAZINE; LOMUSTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKIN METASTASIS; TREATMENT OUTCOME; UVEA MELANOMA;

EID: 0033407109     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199912000-00006     Document Type: Article

References (46)

1. Egan KM, Seddon JM, Glynn R, et al. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988; 32: 239-251.
2. Hungerford J. Uveal melanoma. Eur J Cancer 1993; 29A: 1368-1372.
3. Sahel JA, Steeves RA, Albert DM. Intraocular melanomas. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott, 1997: 1995-2011.
4. Holly EA, Aston DA, Char DH, et al. Uveal melanoma in relation to ultraviolet light exposure and host factors. Cancer Res 1990; 50: 5773-5777.
5. Dolin PJ, Foss AJ, Hungerford JL. Uveal melanoma: is solar ultraviolet radiation a risk factor? Ophthal Epidemiol 1994; 1: 27-30.
6. Schwartz LH, Ferrand R, Boelle PY, et al. Lack of correlation between the location of choroidal melanoma and ultraviolet-radiation dose distribution. Radiation Res 1997; 147: 451-456.
7. Prescher G, Bornfeld N, Becher R. Two subclones in a case of uveal melanoma: relevance of monosomy 3 and multiplication of chromosome 8q. Cancer Genet Cytogenet 1994; 77: 144-146.
8. Singh AD, Wang, MX, Donoso LA, et al. Genetic aspects of uveal melanoma: a brief review. Semin Oncol 1996; 23: 768-772.
9. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1997; 347: 1222-1225.
10. Gamel JW, McLean JW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer 1993; 71: 2299-2305.
11. Dorval T, Desjardins L, Tournet I, et al. Lack of efficacy of adjuvant chemotherapy (dacarbazine) in patients with choroidal melanoma: a prospective randomized study. Proc ASCO 1997; 16: 494a(abstract).
12. Nathan FE, Berd D, Sato T, et al. BOLD + interferon in treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res 1997; 16:201-208.
13. Shields JA, Shields CL, DePotter O, et al. Diagnosis and treatment of uveal melanoma. Semin Oncol 1996; 23: 763-767.
14. Sato T, Babazono A, Shields JA, et al. Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest 1997; 15: 98-105.
15. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer 1983; 52: 334-336.
16. Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992; 36: 429-438.
17. Einhorn LH, Burgess M, Gottlieb JA. Metastatic patterns of choroidal melanoma. Cancer 1974; 34: 1001-1004.
18. Patel JK, Didolkar MS, Pickren WJ, et al. Metastatic pattern of malignant melanoma: a study of 216 autopsy cases. Am J Surg 1978; 135: 807-810.
19. Meyers ML, Balch CM. Diagnosis and treatment of metastatic melanoma. In Balch MC, Houghton AN, Sober AJ, Soong S, eds. Cutaneous Melanoma, 3rd edn. St Louis: QMP, 1998: 325-372.
20. Cantore M, Fiorentini G, Aitini E, et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver: report of a phase II study. Tumori 1994; 80: 37-39.
21. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98: 383-389.
22. McLean IW, Foster WD, Zimmermann LE. Uveal melanoma: localization, size, cell type and enucleation as risk factors in metastasis. Hum Pathol 1982; 13: 123-132.
23. Mooy CM, De Jong PTVM. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996; 41: 215-228.
24. The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma: COMS Report No. 5. Arch Ophthalmol 1997; 115: 1537-1544.
25. Folberg R, Pe'er J, Gruman LM, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma. Hum Pathol 1992; 23: 1298-1305.
26. Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72: 2219-2223.
27. McLean EW, Foster WD, Zimmerman LE. Prognostic factors in small malignant melanoma of the choroid and ciliary body. Arch Ophthalmol 1977; 95: 48-58.
28. Seddon JM, Albert DM, Lavin PT, et al. A prognostic factor study of disease-free survival and survival following enucleation of uveal melanoma. Arch Ophthalmol 1983; 101: 1894-1899.
29. Fine SL. No one knows the preferred management for choroidal melanoma. Am J Ophthalmol 1996; 122: 106-108 (editorial).
30. Coleman DJ. No one knows the preferred management for choroidal melanoma. Am J Ophthalmol 1996; 122: 106-108 (letter, comment).
31. Sellami M, Weil M, Dhermy P, et al. Adjuvant chemotherapy in ocular malignant melanoma. Oncology 1986; 43: 221-223.
32. McLean IW, Berd D, Mastrangelo MJ, et al. A randomized study of methanol-extraction residue of bacille Calmette-Guérin as postsurgical adjuvant therapy in uveal melanoma. Am J Ophthalmol 1990; 110: 522-526.
33. Fournier GA, Albert DM, Arrigg CA, et al. Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma. Arch Ophthalmol 1984; 102: 80-82.
34. Gündüz K, Shields JA, Shields CL, et al. Surgical removal of solitary hepatic metastasis from choroidal melanoma. Am J Ophthalmol 1998; 125: 407-409.
35. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver. A review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76: 1665-1670.
36. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114: 107-108.
37. Nathan FE, Sato T, Hart E, et al. Response to combination chemotherapy of liver metastases from choroidal melanoma compared with cutaneous melanoma. Proc Am Soc Clin Oncol 1994; 13: 394.
38. Proebstle TM, Scheibenbogen C, Sterry W, et al. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma. Eur J Cancer 1996; 32A: 1530-1533.
39. Pyrhönen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10: 1919-1926.
40. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15: 2589-2595.
41. Alexander HR, Bartlett DL, Libutti SK. Isolated hepatic perfusion: a potentially effective treatment for patients with metastatic or primary cancer confined to the liver. Cancer Sci Am 1998; 4: 2-11.
42. Feun LG, Reddy KR, Yrzarry JM, et al. Phase I hepatic chemoembolization trial with cisplatin and lipidol. Proc AACR 1992; 33: A1376 (abstract).
43. De Waard-Siebinga I, Creighton WM, Kool J, et al. Effects of interferon alpha and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol 1995; 79: 847-855.
44. Dorval T, Friedman WH, Mathiot C, et al. Interleukin-2 therapy for metastatic uveal melanoma. Eur J Cancer 1992; 28A: 2087 (letter).
45. Keilholz U, Scheibenbogen C, Brado M, et al. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer 1994; 30A: 103-105.
46. Katato K, Liu PY, Sondak V, et al. Survival and response to treatment in patients with metastatic melanoma from intraocular primaries on SWOG studies. Proc ASCO 1995; 14: 1298(abstract).